News from ACC.25: semaglutide in T2D patients with PAD

Bonaca at ACC

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Low-dose apixaban noninferior to full dose in cancer-associated VTE
Low-dose apixaban noninferior to full dose in cancer-associated VTE
ACC.25
Low-dose apixaban noninferior to full dose in cancer-associated VTE
- Diego Sadler, MD
Expert opinion on the SOUL study results
Expert opinion on the SOUL study results
ACC.25
Expert opinion on the SOUL study results
- Gina Lundberg, MD
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
ACC.25
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
- Gina Lundberg, MD
AI model may accelerate risk stratification of coronary revascularization in ED
AI model may accelerate risk stratification of coronary revascularization in ED
ACC.25
AI model may accelerate risk stratification of coronary revascularization in ED
- Wayne Batchelor, MD